Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Pliant Therapeutics (PLRX) Net Margin (2020 - 2025)

Pliant Therapeutics (PLRX) has disclosed Net Margin for 5 consecutive years, with 15991.91% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin changed N/A to 15991.91% in Q4 2025 year-over-year; TTM through Dec 2025 was 5764.6%, a N/A change, with the full-year FY2023 number at 10211.14%, down 893782.0% from a year prior.
  • Net Margin was 15991.91% for Q4 2025 at Pliant Therapeutics, up from 3227.12% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 15991.91% in Q4 2025 to a low of 16609.68% in Q2 2023.
  • A 4-year average of 16.8% and a median of 1251.68% in 2021 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: soared 68396bps in 2022, then crashed -1601745bps in 2023.
  • Pliant Therapeutics' Net Margin stood at 1227.16% in 2021, then plummeted by -45bps to 1784.22% in 2022, then crashed by -831bps to 16609.68% in 2023, then soared by 196bps to 15991.91% in 2025.
  • Per Business Quant, the three most recent readings for PLRX's Net Margin are 15991.91% (Q4 2025), 3227.12% (Q3 2025), and 5352.29% (Q2 2025).